4.5 Article

Posttranscriptional Suppression of Proto-Oncogene c-fms Expression by Vigilin in Breast Cancer

Journal

MOLECULAR AND CELLULAR BIOLOGY
Volume 31, Issue 1, Pages 215-225

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.01031-10

Keywords

-

Funding

  1. Department of Defense [DAMD 17-02-1-0633]
  2. Arizona Biomedical Research Commission [07-061]
  3. Rodel Foundation
  4. NIH [DK 071909]
  5. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071909] Funding Source: NIH RePORTER

Ask authors/readers for more resources

cis-acting elements found in 3'-untranslated regions (UTRs) are regulatory signals determining mRNA stability and translational efficiency. By binding a novel non-AU-rich 69-nucleotide (nt) c-fms 3' UTR sequence, we previously identified HuR as a promoter of c-fms proto-oncogene mRNA. We now identify the 69-nt c-fms mRNA 3' UTR sequence as a cellular vigilin target through which vigilin inhibits the expression of c-fms mRNA and protein. Altering association of either vigilin or HuR with c-fms mRNA in vivo reciprocally affected mRNA association with the other protein. Mechanistic studies show that vigilin decreased c-fms mRNA stability. Furthermore, vigilin inhibited c-fms translation. Vigilin suppresses while HuR encourages cellular motility and invasion of breast cancer cells. In summary, we identified a competition for binding the 69-nt sequence, through which vigilin and HuR exert opposing effects on c-fms expression, suggesting a role for vigilin in suppression of breast cancer progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available